We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Apple, Pfizer, Intel, Chevron and Exxon Mobil
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 07, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Apple (NASDAQ:AAPL – Free Report), Pfizer, Inc. (NYSE:PFE – Free Report), Intel Corp (NASDAQ:INTC – Free Report), Chevron (NYSE:CVX – Free Report) and Exxon Mobil (NYSE:(XOM - Free Report) – Free Report).
The Dow breached the psychological 22,000 barrier during a week of strong gains. Strong earnings performances were primarily responsible for the index’s record run. The index also received a boost from falling sovereign bond yields on Monday. On Tuesday, the index achieved its 31st record finish for the year.
Ultimately, the index breached the 22,000 barrier on Wednesday. The index gained again on Thursday despite suffering minor losses earlier in the session after the Russia investigation led by Robert Mueller intensified.
Last Week’s Performance
Ultimately, the index breached the 22,000 barrier on Wednesday. The index gained 0.2%, marking its seventh consecutive daily increase. This historic benchmark was achieved within 107 trading days of Dow hitting the 21,000 mark.
This stellar showing was a result of a surge in the shares of Apple Inc. (NASDAQ:AAPL – Free Report) after the tech behemoth posted outstanding earnings results. Broadly encouraging economic conditions also drove the index past the psychological milestone.
The index gained 0.1% on Thursday, index registering its 33rd record for 2017. The index closed above the 22,000 threshold yet again on a day marked by losses for other benchmarks. Further, the blue-chip index notched its eighth straight daily rise, buoyed by an increase in shares of Pfizer, Inc. (NYSE:PFE – Free Report). Early in the session, the blue-chip index had suffered minor losses after the Russia investigation led by Robert Mueller intensified.
Components Moving the Index
Apple reported spectacular results for third-quarter fiscal 2017, driven by the impressive Service segment performance. Earnings of $1.67 per share and revenues of $45.4 billion surpassed the Zacks Consensus Estimate of $1.57 and $44.7 billion, respectively. On a year-over-year basis, earnings grew 17.6% and revenues increased 7.2%. Apple has a Zacks Rank #3.
Total iPhone unit sales came in at about 41 million, up 2% year over year. Revenues from iPhone grew 3% from the year-ago quarter to $24.8 billion (54.7% of total revenue). Services – including revenues from Internet Services, App store, Apple Music, AppleCare, Apple Pay, and licensing and other services – surged 22% year over year to nearly $7.3 billion.
For fourth-quarter fiscal 2017, the company forecasts revenues in a range of $49–$52 billion compared with $46.9 billion reported in the year-ago quarter when it released iPhone 7 and 7 Plus. The Zacks Consensus Estimate is pegged at $49.2 billon. (Read: Apple Q3 Earnings & Revenues Beat Estimates, Stock Up)
Pfizer reported second-quarter 2017 adjusted earnings per share of 67 cents, which beat the Zacks Consensus Estimate of 65 cents by 3.1%. Earnings also rose 5% year over year.
However, the pharma heavyweight delivered revenues of $12.90 billion, which fell short of the Zacks Consensus Estimate of $13.02 billion. Again, revenues declined 2% from the year-ago period due to currency headwinds and divestiture of Hospira infusion systems business. In Feb 2017, Zacks Rank #3 rated Pfizer divested its Hospira infusion systems (HIS) business to ICU Medical.
While Pfizer raised the lower end of its adjusted earnings guidance, it retained the revenue expectations for the year. Revenues are expected in the range of $52 billion to $54 billion. Adjusted earnings per share are expected in the range of $2.54 - $2.60 compared with $2.50–$2.60 expected previously. Higher than previously anticipated royalty income from certain products and lower interest cost led to the increase in the lower end of the profit outlook. (Read: Pfizer Surpasses Q2 Earnings Estimates, Misses Sales)
Intel Corp (NASDAQ:(INTC - Free Report) – Free Report) reported second-quarter 2017 non-GAAP earnings of 72 cents per share, which surged 22% from the year-ago quarter but declined 8.9% sequentially. Earnings per share (EPS) beat the Zacks Consensus Estimate by 4 cents.
The strong year-over-year earnings growth was driven by 9.1% increase in revenues, which totaled $14.76 billion and beat the Zacks Consensus Estimate of $14.41 billion. Revenues were almost flat sequentially. After adjusting for the Intel Security Group (ISecG) transaction, revenues grew 14%.
Intel guided third-quarter 2017 revenues of around $15.7 billion (+/-$500 million), almost flat sequentially and up 3% year over year excluding Intel Security Group business. The projected figure is better than the Zacks Consensus Estimate of $15.35 billion.
For fiscal 2017, management expects revenues of almost $61.3 billion (+/- $500 million), better than the Zacks Consensus Estimate of $60.19 billion and up $1.3 billion from previous expectation. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Chevron (NYSE:(CVX - Free Report) – Free Report) reported strong second-quarter results amid the recovery in commodity prices, production gains and the success of its cost savings initiatives. The company reported earnings per share (excluding special items) of 91 cents, higher than the Zacks Consensus Estimate of 89 cents and the year-ago profit of 48 cents. Quarterly revenue of $34,480 million surpassed the Zacks Consensus Estimate of $31,182 million and increased 18% year over year.
Zacks Rank #3-rated Chevron’s total production of crude oil and natural gas increased 10% compared with last year’s corresponding period to 2,780 thousand oil-equivalent barrels per day (MBOE/d). Chevron’s downstream segment achieved earnings of $1,195 million, 6% less than the profit of $1,278 million last year. The fall primarily underlined the absence of net gains from asset sales. (Read: Chevron Q2 Earnings Beat on Oil Rally, Output Rise)
Exxon Mobil (NYSE:(XOM - Free Report) – Free Report)posted an earnings miss in second-quarter 2017 owing to a decline in liquid volumes and lower margin from chemical businesses. The company reported earnings of 78 cents per share, which missed the Zacks Consensus Estimate of 83 cents. The bottom line improved from the year-ago quarter level of 41 cents. Exxon Mobil has Zacks Rank #4 (Sell).
Total revenue in the quarter increased to $62,876 million from $57,694 million in the year-ago quarter. Moreover, the top line surpassed the Zacks Consensus Estimate of $61,157 million.
Quarterly earnings at the upstream segment were $1.2 billion, up $890 million from the April-to-June quarter of 2016. The downstream segment recorded profits of $1.4 billion. The reported figure is $560 million higher than the April–June quarter of 2016. (Read: Exxon Mobil Q2 Earnings Miss on Lower Volumes)
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Apple, Pfizer, Intel, Chevron and Exxon Mobil
For Immediate Release
Chicago, IL – August 07, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Apple (NASDAQ:AAPL – Free Report), Pfizer, Inc. (NYSE:PFE – Free Report), Intel Corp (NASDAQ:INTC – Free Report), Chevron (NYSE:CVX – Free Report) and Exxon Mobil (NYSE:(XOM - Free Report) – Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Friday’s Analyst Blog:
Dow 30 Stock Roundup: Apple, Pfizer Top Earnings
The Dow breached the psychological 22,000 barrier during a week of strong gains. Strong earnings performances were primarily responsible for the index’s record run. The index also received a boost from falling sovereign bond yields on Monday. On Tuesday, the index achieved its 31st record finish for the year.
Ultimately, the index breached the 22,000 barrier on Wednesday. The index gained again on Thursday despite suffering minor losses earlier in the session after the Russia investigation led by Robert Mueller intensified.
Last Week’s Performance
Ultimately, the index breached the 22,000 barrier on Wednesday. The index gained 0.2%, marking its seventh consecutive daily increase. This historic benchmark was achieved within 107 trading days of Dow hitting the 21,000 mark.
This stellar showing was a result of a surge in the shares of Apple Inc. (NASDAQ:AAPL – Free Report) after the tech behemoth posted outstanding earnings results. Broadly encouraging economic conditions also drove the index past the psychological milestone.
The index gained 0.1% on Thursday, index registering its 33rd record for 2017. The index closed above the 22,000 threshold yet again on a day marked by losses for other benchmarks. Further, the blue-chip index notched its eighth straight daily rise, buoyed by an increase in shares of Pfizer, Inc. (NYSE:PFE – Free Report). Early in the session, the blue-chip index had suffered minor losses after the Russia investigation led by Robert Mueller intensified.
Components Moving the Index
Apple reported spectacular results for third-quarter fiscal 2017, driven by the impressive Service segment performance. Earnings of $1.67 per share and revenues of $45.4 billion surpassed the Zacks Consensus Estimate of $1.57 and $44.7 billion, respectively. On a year-over-year basis, earnings grew 17.6% and revenues increased 7.2%. Apple has a Zacks Rank #3.
Total iPhone unit sales came in at about 41 million, up 2% year over year. Revenues from iPhone grew 3% from the year-ago quarter to $24.8 billion (54.7% of total revenue). Services – including revenues from Internet Services, App store, Apple Music, AppleCare, Apple Pay, and licensing and other services – surged 22% year over year to nearly $7.3 billion.
For fourth-quarter fiscal 2017, the company forecasts revenues in a range of $49–$52 billion compared with $46.9 billion reported in the year-ago quarter when it released iPhone 7 and 7 Plus. The Zacks Consensus Estimate is pegged at $49.2 billon. (Read: Apple Q3 Earnings & Revenues Beat Estimates, Stock Up)
Pfizer reported second-quarter 2017 adjusted earnings per share of 67 cents, which beat the Zacks Consensus Estimate of 65 cents by 3.1%. Earnings also rose 5% year over year.
However, the pharma heavyweight delivered revenues of $12.90 billion, which fell short of the Zacks Consensus Estimate of $13.02 billion. Again, revenues declined 2% from the year-ago period due to currency headwinds and divestiture of Hospira infusion systems business. In Feb 2017, Zacks Rank #3 rated Pfizer divested its Hospira infusion systems (HIS) business to ICU Medical.
While Pfizer raised the lower end of its adjusted earnings guidance, it retained the revenue expectations for the year. Revenues are expected in the range of $52 billion to $54 billion. Adjusted earnings per share are expected in the range of $2.54 - $2.60 compared with $2.50–$2.60 expected previously. Higher than previously anticipated royalty income from certain products and lower interest cost led to the increase in the lower end of the profit outlook. (Read: Pfizer Surpasses Q2 Earnings Estimates, Misses Sales)
Intel Corp (NASDAQ:(INTC - Free Report) – Free Report) reported second-quarter 2017 non-GAAP earnings of 72 cents per share, which surged 22% from the year-ago quarter but declined 8.9% sequentially. Earnings per share (EPS) beat the Zacks Consensus Estimate by 4 cents.
The strong year-over-year earnings growth was driven by 9.1% increase in revenues, which totaled $14.76 billion and beat the Zacks Consensus Estimate of $14.41 billion. Revenues were almost flat sequentially. After adjusting for the Intel Security Group (ISecG) transaction, revenues grew 14%.
Intel guided third-quarter 2017 revenues of around $15.7 billion (+/-$500 million), almost flat sequentially and up 3% year over year excluding Intel Security Group business. The projected figure is better than the Zacks Consensus Estimate of $15.35 billion.
For fiscal 2017, management expects revenues of almost $61.3 billion (+/- $500 million), better than the Zacks Consensus Estimate of $60.19 billion and up $1.3 billion from previous expectation. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Chevron (NYSE:(CVX - Free Report) – Free Report) reported strong second-quarter results amid the recovery in commodity prices, production gains and the success of its cost savings initiatives. The company reported earnings per share (excluding special items) of 91 cents, higher than the Zacks Consensus Estimate of 89 cents and the year-ago profit of 48 cents. Quarterly revenue of $34,480 million surpassed the Zacks Consensus Estimate of $31,182 million and increased 18% year over year.
Zacks Rank #3-rated Chevron’s total production of crude oil and natural gas increased 10% compared with last year’s corresponding period to 2,780 thousand oil-equivalent barrels per day (MBOE/d). Chevron’s downstream segment achieved earnings of $1,195 million, 6% less than the profit of $1,278 million last year. The fall primarily underlined the absence of net gains from asset sales. (Read: Chevron Q2 Earnings Beat on Oil Rally, Output Rise)
Exxon Mobil (NYSE:(XOM - Free Report) – Free Report)posted an earnings miss in second-quarter 2017 owing to a decline in liquid volumes and lower margin from chemical businesses. The company reported earnings of 78 cents per share, which missed the Zacks Consensus Estimate of 83 cents. The bottom line improved from the year-ago quarter level of 41 cents. Exxon Mobil has Zacks Rank #4 (Sell).
Total revenue in the quarter increased to $62,876 million from $57,694 million in the year-ago quarter. Moreover, the top line surpassed the Zacks Consensus Estimate of $61,157 million.
Quarterly earnings at the upstream segment were $1.2 billion, up $890 million from the April-to-June quarter of 2016. The downstream segment recorded profits of $1.4 billion. The reported figure is $560 million higher than the April–June quarter of 2016. (Read: Exxon Mobil Q2 Earnings Miss on Lower Volumes)
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Get the full Report on PFE - FREE
Get the full Report on AAPL - FREE
Get the full Report on INTC - FREE
Get the full Report on CVX - FREE
Get the full Report on XOM - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.